(Q38003702)

26 August 2017

The pharmacogenomics of sex hormone metabolism: breast cancer risk in menopausal hormone therapy (English)

1 reference

26 August 2017

1 reference

3

Hiltrud Brauch

0 references

author name string

Christina Justenhoven

series ordinal

1

1 reference

PubMed ID

22515609

26 August 2017

Ofure Obazee

series ordinal

2

1 reference

26 August 2017

1 April 2012

1 reference

26 August 2017

1 reference

26 August 2017

13

1 reference

26 August 2017

659-675

1 reference

26 August 2017

6

1 reference

Selective estrogen receptor modulation: concept and consequences in cancer

26 August 2017

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

Evidence from randomised trials on the long-term effects of hormone replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

Pharmacogenomics and individualized drug therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

Moving towards individualized medicine with pharmacogenomics

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

Pharmacogenomics: the genetics of variable drug responses

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

Targeting of tamoxifen to enhance antitumour action for the treatment and prevention of breast cancer: the 'personalised' approach?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

Pharmacogenomics of tamoxifen therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

CYP2D6 and tamoxifen: DNA matters in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

CYP2D6 polymorphisms as predictors of outcome in breast cancer patients treated with tamoxifen: expanded polymorphism coverage improves risk stratification

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

Pharmacogenetics and breast cancer endocrine therapy: CYP2D6 as a predictive factor for tamoxifen metabolism and drug response?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

Estrogen and the risk of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

Enzymatic control of estrogen production in human breast cancer: relative significance of aromatase versus sulfatase pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

Estrogen regulation of apoptosis: how can one hormone stimulate and inhibit?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

Current topics and perspectives on the use of aromatase inhibitors in the treatment of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

Estrogen carcinogenesis in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

Estrogen and its metabolites are carcinogenic agents in human breast epithelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

17 beta-estradiol hydroxylation catalyzed by human cytochrome P450 1B1.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

Is estradiol a genotoxic mutagenic carcinogen?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

Inhibition of cellular enzymes by equine catechol estrogens in human breast cancer cells: specificity for glutathione S-transferase P1-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

Catechol estrogen 4-hydroxyequilenin is a substrate and an inhibitor of catechol-O-methyltransferase.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

Equine catechol estrogen 4-hydroxyequilenin is a more potent inhibitor of the variant form of catechol-O-methyltransferase

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

Intratumoral estrogen disposition in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

Tissue estradiol is selectively elevated in receptor positive breast cancers while tumour estrone is reduced independent of receptor status.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

Aromatase expression and outcomes in the P024 neoadjuvant endocrine therapy trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

17ss-Hydroxysteroid dehydrogenase type 1 as predictor of tamoxifen response in premenopausal breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

The multifaceted mechanisms of estradiol and estrogen receptor signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

Mechanisms of endocrine resistance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

The estradiol pharmacophore: ligand structure-estrogen receptor binding affinity relationships and a model for the receptor binding site

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

Catecholestrogens are agonists of estrogen receptor dependent gene expression in MCF-7 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

Regulation of estrogen receptor (ER) levels in MCF-7 cells by progesterone metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

Cellular expression of estrogen and progesterone receptors in mammary glands: regulation by hormones, development and aging

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

Progesterone metabolites in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

Revisiting the duration of vasomotor symptoms of menopause: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

Risk of different histological types of postmenopausal breast cancer by type and regimen of menopausal hormone therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

Estrogen-progestagen menopausal hormone therapy and breast cancer: does delay from menopause onset to treatment initiation influence risks?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

Relationship between long durations and different regimens of hormone therapy and risk of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

Menopausal hormone therapy and subsequent risk of specific invasive breast cancer subtypes in the California Teachers Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

The impact of changes in hormone therapy on breast cancer incidence in the US population.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

Breast cancer incidence rates in U.S. women are no longer declining

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

Trends in hormone therapy and breast cancer incidence - results from the German Network of Cancer Registries

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

Breast cancer after use of estrogen plus progestin in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

Paradoxical clinical effect of estrogen on breast cancer risk: a "new" biology of estrogen-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

An overview of menopausal oestrogen-progestin hormone therapy and breast cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

Association of ESR1 gene tagging SNPs with breast cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

Genome-wide association study provides evidence for a breast cancer risk locus at 6q22.33.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

Germline E-cadherin mutations in familial lobular breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

Advances in breast cancer: pathways to personalized medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

Genome-wide association study identifies five new breast cancer susceptibility loci

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

Genome-wide association study identifies a new breast cancer susceptibility locus at 6q25.1.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

Genomewide association studies and human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

Variation in the FGFR2 gene and the effects of postmenopausal hormone therapy on invasive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

Estrogen-biosynthesis gene CYP17 and its interactions with reproductive, hormonal and lifestyle factors in breast cancer risk: results from the Long Island Breast Cancer Study Project.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

Postmenopausal estrogen monotherapy-associated breast cancer risk is modified by CYP17A1_-34_T>C polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

The CYP1B1_1358_GG genotype is associated with estrogen receptor-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

Factors modifying the association between hormone-replacement therapy and breast cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

Role of polymorphic human cytochrome P450 enzymes in estrone oxidation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

CYP2C19*17 is associated with decreased breast cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

Estrogen receptor polymorphisms and the risk of endometrial cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

Genetic polymorphisms in the estrogen receptor beta (ESR2) gene and the risk of epithelial ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

Inhibition of p160-mediated coactivation with increasing androgen receptor polyglutamine length

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

Polymorphisms of the androgen receptor gene and the estrogen receptor beta gene are associated with androgen levels in women

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

Orphan nuclear receptors: the exotics of xenobiotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

Genome-wide association study identifies novel breast cancer susceptibility loci

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

Blocking of FGFR signaling inhibits breast cancer cell proliferation through downregulation of D-type cyclins

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

Differential signal transduction of alternatively spliced FGFR2 variants expressed in human mammary epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

Genome-wide analysis of estrogen receptor binding sites

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

The combined immunodetection of AP-2alpha and YY1 transcription factors is associated with ERBB2 gene overexpression in primary breast tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

Inhibition of Yin Yang 1-dependent repressor activity of DR5 transcription and expression by the novel proteasome inhibitor NPI-0052 contributes to its TRAIL-enhanced apoptosis in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

Carboxyl-terminal Src kinase homologous kinase negatively regulates the chemokine receptor CXCR4 through YY1 and impairs CXCR4/CXCL12 (SDF-1alpha)-mediated breast cancer cell migration

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

Hormone-dependent effects of FGFR2 and MAP3K1 in breast cancer susceptibility in a population-based sample of post-menopausal African-American and European-American women

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

A retrospective case-control study of the use of hormone-related supplements and association with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

P53, apoptosis, and breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

Clinical aspects of the MDR1 (ABCB1) gene polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

P-glycoprotein (P-gp/MDR1)-mediated efflux of sex-steroid hormones and modulation of P-gp expression in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

BRCA1 and BRCA2 and the genetics of breast and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

Association of BRCA1 with Rad51 in mitotic and meiotic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

Increase of androgen-induced cell death and androgen receptor transactivation by BRCA1 in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

Estrogen treatment induces MLL aberrations in human lymphoblastoid cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

Involvement of genotoxic effects in the initiation of estrogen-induced cellular transformation: studies using Syrian hamster embryo cells treated with 17beta-estradiol and eight of its metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

Effect modification by catalase genotype suggests a role for oxidative stress in the association of hormone replacement therapy with postmenopausal breast cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

Associations between catalase phenotype and genotype: modification by epidemiologic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

Genotype-activity relationship for Mn-superoxide dismutase, glutathione peroxidase 1 and catalase in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

Association of CAT polymorphisms with catalase activity and exposure to environmental oxidative stimuli.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

The equine estrogen metabolite 4-hydroxyequilenin causes DNA single-strand breaks and oxidation of DNA bases in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

The major metabolite of equilin, 4-hydroxyequilin, autoxidizes to an o-quinone which isomerizes to the potent cytotoxin 4-hydroxyequilenin-o-quinone

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

Current status of genome-wide association studies in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

Breast cancer and hormone-replacement therapy: the Million Women Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

Activity Levels of Tamoxifen Metabolites at the Estrogen Receptor and the Impact of Genetic Polymorphisms of Phase I and II Enzymes on Their Concentration Levels in Plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

Common variants on chromosome 5p12 confer susceptibility to estrogen receptor–positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

Genetic polymorphisms in phase I and phase II enzymes and breast cancer risk associated with menopausal hormone therapy in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

Polymorphisms in the BRCA1 and ABCB1 genes modulate menopausal hormone therapy associated breast cancer risk in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.144

21 January 2018

Identifiers

DOI

10.2217/PGS.11.144

1 reference

26 August 2017

1 reference

PubMed ID

22515609